Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT for the treatment of generalized anxiety disorder (GAD). The study met its primary endpoint with a statistically significant reduction in HAM-A scores compared to placebo (p<0.0001) and was generally well tolerated. The company plans to file an NDA in the first half of 2027 following a pre-NDA meeting with the FDA in Q4 2026.
Telomir Pharmaceuticals announced positive preclinical in-vitro research findings demonstrating that its compound Telomir-Zn inhibited cell growth in both human and canine osteosarcoma models. The study, conducted with The Ohio State University, showed consistent anti-tumor activity at low drug concentrations, supporting a potential parallel development pathway for veterinary and human oncology indications.
Counterparty
The Ohio State University College of Veterinary Medicine
Cullinan Therapeutics and Taiho announced positive results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation-positive NSCLC. The trial met its primary endpoint, showing a statistically significant median progression-free survival of 14.5 months compared to 8.5 months for chemotherapy alone (HR 0.50).
Corbus Pharmaceuticals Holdings Clinical Trial Data
Corbus Pharmaceuticals announced positive topline results from its CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The study met its primary objectives, demonstrating statistically significant weight loss of 5% at the 60 mg dose over 12 weeks with a favorable safety profile and no evidence of weight loss plateauing. The data supports CRB-913's potential as a first-in-class oral, non-incretin obesity medicine.
Lipocine Inc. announced the initiation of BLOOM, a Phase 3 clinical study evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. The study aims to enroll approximately 120 participants with first dosing expected in early Q4 2026, following exploratory findings from a prior trial that suggested rapid symptom relief.